$AACT
Ares Acquisition Corp II

2023 Q4 Form 10-K Financial Statement

#000162828024007635 Filed on February 28, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023 2022
Revenue $0.00 $18.04M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $431.4K $1.123M
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $431.4K $1.123M $0.00
YoY Change -100.0%
Operating Profit -$1.123M -$3.542K
YoY Change 31602.2%
Interest Expense $7.381M $18.04M
YoY Change
% of Operating Profit
Other Income/Expense, Net $18.04M $0.00
YoY Change
Pretax Income $6.950M $16.92M $0.00
YoY Change -100.0%
Income Tax
% Of Pretax Income
Net Earnings $6.950M $16.92M $0.00
YoY Change -100.0%
Net Earnings / Revenue 93.77%
Basic Earnings Per Share
Diluted Earnings Per Share $0.15 $0.36 $0.00
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.905M $1.905M
YoY Change
Cash & Equivalents $1.905M
Short-Term Investments
Other Short-Term Assets $510.0K $510.0K $0.00
YoY Change
Inventory
Prepaid Expenses $510.0K
Receivables
Other Receivables
Total Short-Term Assets $2.415M $2.415M $0.00
YoY Change 201156.08%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $523.0M $523.0M
YoY Change
Other Assets $0.00 $0.00 $510.0K
YoY Change -100.0% 21.43%
Total Long-Term Assets $523.0M $523.0M $510.0K
YoY Change 102176.78% 102456.54% 21.43%
TOTAL ASSETS
Total Short-Term Assets $2.415M $2.415M $0.00
Total Long-Term Assets $523.0M $523.0M $510.0K
Total Assets $525.5M $525.5M $510.0K
YoY Change 102408.5% 102930.08% 21.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $271.6K $271.6K $270.0K
YoY Change 0.46% 0.6% 22.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $230.0K
YoY Change -100.0% 27.78%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $279.1K $279.1K $500.0K
YoY Change -44.58% -44.17% 25.0%
LONG-TERM LIABILITIES
Long-Term Debt $5.000M $5.000M $0.00
YoY Change
Other Long-Term Liabilities $17.50M $17.50M
YoY Change
Total Long-Term Liabilities $5.000M $22.50M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $279.1K $279.1K $500.0K
Total Long-Term Liabilities $5.000M $22.50M $0.00
Total Liabilities $22.78M $22.78M $500.0K
YoY Change 4422.95% 4455.83% 25.0%
SHAREHOLDERS EQUITY
Retained Earnings -$20.27M
YoY Change 126250.21%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$20.26M $502.7M $10.00K
YoY Change
Total Liabilities & Shareholders Equity $525.5M $525.5M $510.0K
YoY Change 102408.5% 102930.08% 21.43%

Cashflow Statement

Concept 2023 Q4 2023 2022
OPERATING ACTIVITIES
Net Income $6.950M $16.92M $0.00
YoY Change -100.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$264.4K -$1.353M $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$505.0M
YoY Change
Cash From Investing Activities $0.00 -$505.0M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -85.00K $508.3M $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -264.4K -$1.353M 0.000
Cash From Investing Activities 0.000 -$505.0M $0.00
Cash From Financing Activities -85.00K $508.3M $0.00
Net Change In Cash -349.4K $1.905M 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$264.4K -$1.353M $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
99990000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q2 aac Number Of Business Days To Redeem Public Shares If No Business Combination
NumberOfBusinessDaysToRedeemPublicSharesIfNoBusinessCombination
P10D
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
99990000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
99990000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
523038352 usd
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
100
CY2023 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2023 dei Auditor Location
AuditorLocation
New York, New York
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1905123 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
509950 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1200 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2415073 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1200 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
523038352 usd
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
0 usd
CY2023Q4 aac Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
0 usd
CY2022Q4 aac Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
511395 usd
CY2023Q4 us-gaap Assets
Assets
525453425 usd
CY2022Q4 us-gaap Assets
Assets
512595 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
271633 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
270391 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7500 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
0 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
279133 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
503634 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5000000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 usd
CY2023Q4 aac Deferred Underwriting And Advisory Fees
DeferredUnderwritingAndAdvisoryFees
17500000 usd
CY2022Q4 aac Deferred Underwriting And Advisory Fees
DeferredUnderwritingAndAdvisoryFees
0 usd
CY2023Q4 us-gaap Liabilities
Liabilities
22779133 usd
CY2022Q4 us-gaap Liabilities
Liabilities
503634 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
522938352 usd
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
0 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
99990000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
99990000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23750 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20265310 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16039 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-20264060 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8961 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
525453425 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
512595 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1122892 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3542 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-1122892 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-3542 usd
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
18038352 usd
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
0 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18038352 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
12503 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3542 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8961 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
14300000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
2625000 usd
CY2023 aac Adjustments To Additional Paid In Capital Common Stock Accretion To Redemption Value
AdjustmentsToAdditionalPaidInCapitalCommonStockAccretionToRedemptionValue
54113481 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-20264060 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
16915460 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3542 usd
CY2023 us-gaap Net Investment Income
NetInvestmentIncome
18038352 usd
CY2022 us-gaap Net Investment Income
NetInvestmentIncome
0 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
508750 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
271633 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 usd
CY2023 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
7500 usd
CY2022 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
0 usd
CY2023 aac Payment Of Formation Costs Through Promissory Note
PaymentOfFormationCostsThroughPromissoryNote
0 usd
CY2022 aac Payment Of Formation Costs Through Promissory Note
PaymentOfFormationCostsThroughPromissoryNote
3542 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1352509 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 usd
CY2023 us-gaap Payments To Acquire Trust Preferred Investments
PaymentsToAcquireTrustPreferredInvestments
505000000 usd
CY2022 us-gaap Payments To Acquire Trust Preferred Investments
PaymentsToAcquireTrustPreferredInvestments
0 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-505000000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
500000000 usd
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
14300000 usd
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0 usd
CY2023 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
5000000 usd
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 usd
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
366781 usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2023 aac Payment Of Underwriter And Advisory Fee
PaymentOfUnderwriterAndAdvisoryFee
10000000 usd
CY2022 aac Payment Of Underwriter And Advisory Fee
PaymentOfUnderwriterAndAdvisoryFee
0 usd
CY2023 aac Cash Payments Of Stock Issuance Costs
CashPaymentsOfStockIssuanceCosts
675587 usd
CY2022 aac Cash Payments Of Stock Issuance Costs
CashPaymentsOfStockIssuanceCosts
0 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
508257632 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1905123 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1905123 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023 aac Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
270391 usd
CY2022 aac Deferred Offering Costs Incurred But Not Yet Paid
DeferredOfferingCostsIncurredButNotYetPaid
-49439 usd
CY2023 aac Deferred Offering Costs Incurred And Paid By Affiliate
DeferredOfferingCostsIncurredAndPaidByAffiliate
133538 usd
CY2022 aac Deferred Offering Costs Incurred And Paid By Affiliate
DeferredOfferingCostsIncurredAndPaidByAffiliate
45788 usd
CY2023 aac Deferred Underwriting And Advisory Fees Non Cash
DeferredUnderwritingAndAdvisoryFeesNonCash
17500000 usd
CY2022 aac Deferred Underwriting And Advisory Fees Non Cash
DeferredUnderwritingAndAdvisoryFeesNonCash
0 usd
CY2023Q2 aac Initial Business Combination Fair Market Value Percentage Of Assets In Trust Account
InitialBusinessCombinationFairMarketValuePercentageOfAssetsInTrustAccount
0.80
CY2023Q2 aac Initial Business Combination Threshold Percentage Of Outstanding Voting Securities
InitialBusinessCombinationThresholdPercentageOfOutstandingVotingSecurities
0.50
CY2023Q2 aac Initial Business Combination Share Conversion Percentage Threshold Requiring Company Consent
InitialBusinessCombinationShareConversionPercentageThresholdRequiringCompanyConsent
0.15
CY2023Q2 aac Share Redemption Threshold If No Business Combination Occurs
ShareRedemptionThresholdIfNoBusinessCombinationOccurs
1
CY2023Q2 aac Initial Business Combination Interest Income To Pay Liquidation Expenses Maximum
InitialBusinessCombinationInterestIncomeToPayLiquidationExpensesMaximum
100000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1905123 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
523038352 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></div>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition.</span></div>
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2021Q1 aac Sale Of Stock Underwriter Over Allotment Purchase Period
SaleOfStockUnderwriterOverAllotmentPurchasePeriod
45 tradingday
CY2021Q1 aac Sale Of Stock Number Of Shares Issuable In Transaction
SaleOfStockNumberOfSharesIssuableInTransaction
6750000 shares
CY2023Q4 aac Business Combination Contingent Fee Amount
BusinessCombinationContingentFeeAmount
734573 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
99990000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 aac Business Combination Period For Registration Statement To Become Effective
BusinessCombinationPeriodForRegistrationStatementToBecomeEffective
P60D
CY2023Q4 aac Business Combination Period For Registration Statement To Become Effective
BusinessCombinationPeriodForRegistrationStatementToBecomeEffective
P60D

Files In Submission

Name View Source Status
0001628280-24-007635-index-headers.html Edgar Link pending
0001628280-24-007635-index.html Edgar Link pending
0001628280-24-007635.txt Edgar Link pending
0001628280-24-007635-xbrl.zip Edgar Link pending
aac-20231231.htm Edgar Link pending
aac-20231231.xsd Edgar Link pending
aaciiq42023exhibit311.htm Edgar Link pending
aaciiq42023exhibit312.htm Edgar Link pending
aaciiq42023exhibit321.htm Edgar Link pending
aaciiq42023exhibit322.htm Edgar Link pending
aaciiq42023exhibit45.htm Edgar Link pending
aaciiq42023exhibit971.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
aac-20231231_def.xml Edgar Link unprocessable
aac-20231231_htm.xml Edgar Link completed
aac-20231231_lab.xml Edgar Link unprocessable
aac-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
aac-20231231_cal.xml Edgar Link unprocessable